医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 10% 医药生物 沪深300 标配（维持） 医药生物行业双周报（2025/9/26-2025/10/9） 第十一批国采月底申报 投资要点： 相关报告 证 券 研 究 报 告 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 邮箱： xiexiongxiong@dgzq.com.cn 医药生物（申万）指数走势 资料来源：iFind，东莞证券研究所 2025 年 ...

格隆汇10月9日丨润都股份(002923.SZ)公布，公司于2025年05月14日至2025年05月16日接受了欧洲药品 质量管理局（简称"EDQM"）对原料药CEP（欧洲药典适用性证书）的现场GMP检查。近日，公司收到 了EDQM签发的《检查证明》，此次检查顺利通过。本次公司收到EDQM的检查证明文件，表明公司的 药品生产活动持续符合欧盟GMP的要求，为公司进一步开拓欧洲原料药市场奠定了坚实基础，为公司 持续拓展国际市场注入动力，对提升公司综合竞争力及推动未来发展具有积极促进作用。 ...

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.2% from September 22 to September 26, underperforming compared to the Wind All A index (0.25%) and the CSI 300 index (1.07%) [3][8] - The flu season is becoming active, with monitoring data indicating a slow upward trend in respiratory infectious diseases, particularly in southern provinces [3][12] - The upcoming ESMO conference from October 17 to 21 in Berlin will feature significant research contributions from Chinese scholars, with 23 studies included in the Late-Breaking Abstracts [3][12] Market Weekly Review - The pharmaceutical and biotechnology sector declined by 2.2%, with only the other biological products sector showing a slight increase of 0.05%. The raw materials sector saw a significant drop of 8.22% [8][9] - Notable stock performances included Sunflower (57.9% increase), Aopumai (23.9% increase), and Xinlitai (15.8% increase), while Borui Pharmaceutical (-38.4%) and Zhongsheng Pharmaceutical (-14%) faced significant declines [11][12] Industry News and Key Company Announcements - The National Healthcare Security Administration launched a "100-day action" to address prominent issues in medical insurance fund management, effective until December 31, 2025 [12][13] - Pfizer announced its acquisition of Metsera for approximately $4.9 billion, focusing on developing next-generation obesity and cardiometabolic disease drugs [16][17] - The ESMO conference has highlighted 23 groundbreaking studies from Chinese researchers, marking a significant achievement for the industry [16][17]

2025Q3 医药业绩前瞻 20250928 摘要 创新药板块经历调整后，头部公司如信达生物、中国生物制药等基本面 稳健，产品进度符合预期，具备配置价值。自下而上选股策略关注业绩 兑现能力强的公司，如诚信生物、诺诚健华等。ISMO 大会中国公司 LBA 数量创新高，建议关注乐普生物等。 医疗器械板块受益于反内卷，高值耗材如南微医学、心脉医疗等未集采 赛道释放压力。骨科行业走出集采阴霾，春立爱康等业绩亮眼。医疗设 备领域，迈瑞、开立医疗等国内招标市场为主的公司有望受益于反内卷。 定制耗材领域表现良好，英科医疗二季度利润超预期，三季度订单排期 延长，预计明年业绩增长。IVD 板块虽受集采和税率调整影响承压，但 底部已夯实，迈瑞亚、新产业等海外出口表现突出。 中药板块推荐九芝堂、康缘药业和华润三九。九芝堂作为干细胞龙头， 其脑卒中管线潜力巨大。康缘药业减肥药三靶点进展迅速，双靶点安全 性良好。华润三九战略方向发生变化，重视创新产品商业化。 原料药行业有望受益于反内卷政策，迎来新一轮供给侧改革。天宇股份 等公司在专利到期新产品快速放量、高端市场制剂一体化以及 CDMO 业 务板块拉动下，产能利用率快速提升，业绩有望爆 ...

Group 1: Pharmaceutical Industry - The domestic raw material pharmaceutical industry is at the bottom of the cycle, with some companies actively transitioning to innovative drug development, which may lead to a harvest period [1] - The raw material drug sector has experienced a four-year downward cycle, with prices of various products, including sartans and heparins, reaching historical lows, resulting in some leading companies operating at a loss [1] - Companies like Huahai Pharmaceutical and Borui Pharmaceutical are focusing on innovative drugs in oncology and autoimmune fields, with several products in various clinical trial stages [2] Group 2: Vaccine and Blood Products Sector - The vaccine industry is facing a continuous decline in performance due to a decrease in newborn numbers and changes in the competitive landscape, although some companies are gradually adopting new technologies and products [3] - The blood products sector is also at the bottom of the cycle, with revenue and net profit expected to decline in 2025 due to inventory levels and demand suppression from medical insurance [3] - The consolidation of leading companies in the blood products industry is expected to increase industry concentration and stabilize pricing [3] Group 3: Medical Services Sector - The medical services sector is experiencing a decline in performance due to DRGs and the consumption environment, with a shift towards utilizing AI technology to enhance the capabilities of primary doctors [4] - The core competitiveness of the medical services industry lies in acquiring and training quality doctors and hospital management, with AI expected to improve patient coverage and diagnostic capabilities [4]

Group 1: Pharmaceutical Industry - The active pharmaceutical ingredient (API) industry has experienced a downturn over the past four years, with prices of various products, including sartans, heparins, and animal health products, reaching historical lows, leading to some leading companies operating at a loss [7][8][10] - In the first half of 2025, the API sector saw a decline in both revenue and net profit due to significant price drops in anti-infective products and increased R&D investments by some companies [7][10] - Domestic API companies are actively transitioning to innovative drug development, with several products in various clinical trial stages, indicating a shift towards higher-value offerings [7][10] Group 2: Real Estate Industry - The stabilization of housing prices is influenced by multiple factors, including monetary policy, supply-demand relationships, and economic expectations, rather than solely by population changes [3][12][15] - Analysis of housing price data from 70 cities shows that both new and second-hand housing prices have been in a downward trend since 2022, with a recent narrowing of year-on-year declines due to supportive policies [12][13] - Recommendations for investment focus on strong credit real estate companies with good fundamentals and leading product capabilities, as well as those benefiting from dual-driven residential and commercial real estate strategies [15] Group 3: IT Services Industry - The company is a leading player in the domestic IT services sector and a key partner of Huawei, with over 40% of its revenue derived from this partnership [4][17][20] - The company's cloud intelligence business is experiencing significant growth, and it is expected to benefit from the development of the HarmonyOS ecosystem and AI technologies [4][17][20] - Profit forecasts for 2025-2027 have been adjusted, with expected net profits of 564 million, 628 million, and 708 million yuan respectively, reflecting a strategic focus on AI and cloud services [4][17][20] Group 4: Alibaba Group - Alibaba is actively advancing its AI infrastructure and plans to increase investments, which is expected to accelerate growth in its cloud business [5][21][22] - The demand for AI infrastructure is exceeding expectations, with plans to invest 380 billion yuan in building AI infrastructure, significantly increasing the energy consumption scale of its global data centers by 10 times by 2032 [5][21][22] - The company aims to enhance its market position through comprehensive AI-driven strategies, including improvements in its e-commerce platform and cloud services [21][22][23]

相关研究报告 《集采优化叠加创新驱动，Pharma 迎 来 发 展 新 阶 段 — 行 业 点 评 报 告 》 -2025.9.22 医药生物 2025 年 09 月 24 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 0% 12% 24% 36% 48% 60% 2024-09 2025-01 2025-05 2025-09 医药生物 沪深300 《创新药行业进入快速成长期，关注 未来 6-12 个月投资机会—行业周报》 -2025.9.14 《中药及医药商业 2025H1 复盘：短期 承压，静待花开—行业点评报告》 -2025.9.8 原料药公司加速创新药布局，AI+医疗布局逐步深化 ——行业深度报告 | 余汝意（分析师） | 阮帅（分析师） | | --- | --- | | yuruyi@kysec.cn | ruanshuai@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790524040007 | 原料药板块：创新转型正当时 原料药行业经历近 4 年周期下行，各类产品价格跌至部分龙头企业处于亏损的阶段， 行业整体处于底部区域，其中沙坦类、肝素类、动 ...

Company Overview - Huangshan Capsule Co., Ltd. is located in Anhui Province and was established on August 12, 1996, with its listing date on October 25, 2016 [2] - The company specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [2] - The revenue composition includes gelatin hollow capsules (64.54%), enteric-coated gelatin hollow capsules (19.22%), and plant capsules and others (16.24%) [2] Stock Performance - As of September 23, the stock price of Huangshan Capsule decreased by 2.01% to 7.32 CNY per share, with a total market capitalization of 2.189 billion CNY [1] - Year-to-date, the stock price has increased by 18.16%, but it has seen a decline of 5.91% over the last five trading days, 9.85% over the last 20 days, and 1.88% over the last 60 days [2] Financial Performance - For the period from January to June 2025, Huangshan Capsule achieved a revenue of 244 million CNY, representing a year-on-year growth of 3.66% [2] - The net profit attributable to the parent company was 35.55 million CNY, showing a year-on-year increase of 19.78% [2] Shareholder Information - As of June 30, 2025, the number of shareholders was 17,900, a decrease of 2.57% from the previous period [2] - The average circulating shares per person increased by 2.64% to 16,197 shares [2] - The company has distributed a total of 125 million CNY in dividends since its A-share listing, with 62.81 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) held 1.6367 million shares, an increase of 129,400 shares from the previous period [3] - Nu'an Multi-Strategy Mixed A Fund (320016) entered as a new shareholder, holding 1.3943 million shares [3]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong demand, resulting in sustained high growth in sales of domestic new drugs, with several innovative pharmaceutical companies turning losses into profits and entering a stable growth phase [2]. Pharmaceutical Industry Overview - Innovative Drugs: The industry is witnessing a significant increase in the sales of domestic new drugs driven by strong demand, with several companies achieving profitability [2]. - Medical Devices: The high-value consumables sector is seeing mild price reductions, with ongoing domestic substitution and accelerated overseas business progress. The collection and procurement in neurosurgery and neurointervention fields are stabilizing, and new products are expected to drive growth [2]. - Blood Products: The market share is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape. Demand is expected to upgrade towards new products, enhancing industry prosperity [3]. - API (Active Pharmaceutical Ingredients): The end of the capital expenditure peak, combined with three growth drivers, indicates a clear upward turning point for the industry, with leading companies expected to see significant revenue and profit growth [3]. - CXO (Contract Research Organization): The CDMO sector is stabilizing in core business profitability while emerging fields like peptides and ADCs are rapidly growing, enhancing corporate profitability [3]. - Traditional Chinese Medicine and Retail: The hospital sector is recovering, while the retail sector is expected to gradually improve in performance as inventory is digested [3]. Research and Development Trends - The domestic innovative drug business development (BD) is heating up, likely boosting downstream demand recovery. Domestic companies are improving their technology, products, and services, establishing brand effects, and benefiting from the ongoing tariff war with the U.S. [4]. - The research service sector is expected to see improved financial indicators for leading companies due to supply-demand improvements and an upward cycle [4]. Investment Strategy and Market Dynamics - The pharmaceutical industry has published a total of 260 research reports since October 1 of last year, indicating a robust analytical framework and ongoing market engagement [5]. - The medical device sector is expected to see a recovery in performance in the second half of 2025, with ongoing upgrades in product offerings and expansion into overseas markets [2][3]. Summary of Reports and Meetings - The company has conducted numerous offline strategy meetings and expert discussions, indicating active engagement with industry stakeholders and investors [15].